VEGFA and hepatocellular carcinoma: In fact, the immunological response after locoregional therapies seems to be magnified by checkpoint blockade and even more intensified by the add on of MKIs/anti-VEGF agents, both able of further remodeling the composition of the HCC microenvironment in favor of an antitumoral effect inducing the transformation of a non-immunogenic “cold” into an inflamed “hot” tumor [40,41,42].